Substance / Medication

Tipiracil hydrochloride

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Neoplasm of large intestine

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Trifluridine and Tipiracil Hydrochloride Combination-Induced Interstitial Pneumonia: A Case Report.

Nakazawa Shun, Kato Motoyasu, Terayama Yuriko et al. · Int Med Case Rep J · 2024

PMID: 38344468Case ReportFull text (PMC)

Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy.

Sunakawa Yu, Izawa Naoki, Mizukami Takuro et al. · Onco Targets Ther · 2017

PMID: 28979148ReviewFull text (PMC)

[Antitumor Molecular Mechanism of Trifluridine and Tipiracil Hydrochloride (TAS-102: TFTD)].

Kitao Hiroyuki, Matsuoka Kazuaki, Iimori Makoto et al. · Gan To Kagaku Ryoho · 2016

PMID: 26809521Review

Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS).

Chida Keigo, Kotani Daisuke, Moriwaki Toshikazu et al. · Front Oncol · 2021

PMID: 33763345OtherFull text (PMC)

Decreased percentage of neutrophil is a predict factor for the efficacy of trifluridine and tipiracil hydrochloride for pretreated metastatic colorectal cancer.

Makihara Katsuya, Fukui Rino, Uchiyama Hitomi et al. · J Gastrointest Oncol · 2019

PMID: 31602325OtherFull text (PMC)

Economic evaluation of trifluridine and tipiracil hydrochloride in the treatment of metastatic colorectal cancer in Greece.

Gourzoulidis George, Maniadakis Nikos, Petrakis Dimitrios et al. · J Comp Eff Res · 2019

PMID: 30547679Other

[Regorafenib and Trifluridine and Tipiracil Hydrochloride Can Potentially Improve the Survival Time for Patients with Advanced or Recurrent Colorectal Cancer].

Oki Masataka, Nakamura Akira, Shinamura Naoya et al. · Gan To Kagaku Ryoho · 2018

PMID: 30237371Other

Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer.

Mulet N, Matos I, Noguerido A et al. · Expert Opin Pharmacother · 2018

PMID: 29537896Other

Self-Reported Adherence to Trifluridine and Tipiracil Hydrochloride for Metastatic Colorectal Cancer: A Retrospective Cohort Study.

Sugita Kazuo, Kawakami Kazuyoshi, Yokokawa Takashi et al. · Oncology · 2016

PMID: 27513940Other

Targeting Thymidine Phosphorylase With Tipiracil Hydrochloride Attenuates Thrombosis Without Increasing Risk of Bleeding in Mice.

Belcher Adam, Zulfiker Abu Hasanat Md, Li Oliver Qiyue et al. · Arterioscler Thromb Vasc Biol · 2021

PMID: 33297751PreclinicalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Tipiracil hydrochloride (substance)
SNOMED CT: 724030003
UMLS CUI: C4056442

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.